Monday, November 20, 2017 10:17:18 AM
the HeartSentry, a new non-invasive diagnostic tool for accurately measuring
and monitoring cardiovascular health.
• The HeartSentry measures the function of the endothelium – the critical inner
lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the
company.
• Lexington is in final stages of releasing the product into clinical studies for FDA
approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general
practitioners, and ultimately patients first line evaluation of cardiovascular
health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized
medicine.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM